These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1992599)

  • 1. Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review.
    Du Plessis DJ
    Urology; 1991; 37(2 Suppl):20-4. PubMed ID: 1992599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group.
    Dijkman GA; Janknegt RA; De Reijke TM; Debruyne FM
    J Urol; 1997 Jul; 158(1):160-3. PubMed ID: 9186345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma.
    Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM; Tewari HD
    Cancer; 1990 Sep; 66(5 Suppl):1074-9. PubMed ID: 2203517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of Anandron with orchiectomy in treatment of metastatic prostate cancer. Results of a double-blind study.
    Beland G
    Urology; 1991; 37(2 Suppl):25-9. PubMed ID: 1992600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.
    Janknegt RA; Abbou CC; Bartoletti R; Bernstein-Hahn L; Bracken B; Brisset JM; Da Silva FC; Chisholm G; Crawford ED; Debruyne FM
    J Urol; 1993 Jan; 149(1):77-82; discussion 83. PubMed ID: 7678043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).
    Bertagna C; De Géry A; Hucher M; François JP; Zanirato J
    Br J Urol; 1994 Apr; 73(4):396-402. PubMed ID: 8199827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
    Kuhn JM; Billebaud T; Navratil H; Moulonguet A; Fiet J; Grise P; Louis JF; Costa P; Husson JM; Dahan R
    N Engl J Med; 1989 Aug; 321(7):413-8. PubMed ID: 2503723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nilutamide: an antiandrogen for the treatment of prostate cancer.
    Dole EJ; Holdsworth MT
    Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group.
    Janknegt RA
    Cancer; 1993 Dec; 72(12 Suppl):3874-7. PubMed ID: 8252507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total androgen ablation: Canadian experience.
    Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM; Tewari HD
    Urol Clin North Am; 1991 Feb; 18(1):75-82. PubMed ID: 1992574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved subjective responses to orchiectomy plus nilutamide (anandron) in comparison to orchiectomy plus placebo in metastatic prostate cancer. International Anandron Study Group.
    Dijkman GA; Fernandez del Moral P; Debruyne FM; Janknegt RA
    Eur Urol; 1995; 27(3):196-201. PubMed ID: 7601182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer.
    Bélanger A; Dupont A; Labrie F
    J Clin Endocrinol Metab; 1984 Sep; 59(3):422-6. PubMed ID: 6086697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total androgen blockade for metastatic cancer of the prostate.
    Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM
    Am J Clin Oncol; 1988; 11 Suppl 2():S187-90. PubMed ID: 3149456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
    Kassouf W; Tanguay S; Aprikian AG
    J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anandron (nilutamide) combined with orchiectomy in stage D prostate cancer patients. Overview of seven randomized placebo controlled studies.
    Hucher M; de Gery A; Bertagna C
    Cancer; 1993 Dec; 72(12 Suppl):3886-7. PubMed ID: 8252510
    [No Abstract]   [Full Text] [Related]  

  • 16. Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogen.
    Sarosdy MF
    Anticancer Drugs; 1999 Oct; 10(9):791-6. PubMed ID: 10587288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.
    Harris MG; Coleman SG; Faulds D; Chrisp P
    Drugs Aging; 1993; 3(1):9-25. PubMed ID: 8453188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
    J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.
    Decensi AU; Boccardo F; Guarneri D; Positano N; Paoletti MC; Costantini M; Martorana G; Giuliani L
    J Urol; 1991 Aug; 146(2):377-81. PubMed ID: 1856935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of antiandrogens and value of combining androgen suppression with antiandrogen therapy.
    Gaillard-Moguilewsky M
    Urology; 1991; 37(2 Suppl):5-12. PubMed ID: 1992602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.